Key result
Pre-EVT tirofiban is linked to ~43% lower odds of functional independence in women versus men.
Why the study?
Intravenous tirofiban before EVT did not improve 90-day outcomes in the RESCUE BT trial, leaving sex-specific heterogeneity uncertain.
Does intravenous tirofiban improve 90-day functional outcomes differently by sex in patients with large vessel occlusion stroke undergoing endovascular treatment?
Does intravenous tirofiban improve 90-day functional outcomes differently by sex in patients with large vessel occlusion stroke undergoing endovascular treatment?
This post hoc analysis found no significant interaction between sex and tirofiban treatment for 90-day functional outcomes in patients with large vessel occlusion stroke undergoing endovascular treatment.
Answers are grounded in this paper and cite their sources.
No sex-specific benefit of pre-EVT tirofiban identified; leaves open whether dedicated trials stratified by sex are warranted.
Background Intravenous tirofiban administered before endovascular treatment (EVT) did not improve 90-day outcomes compared to placebo in the RESCUE BT trial, and sex-specific heterogeneity remained uncertain. In this study, we aimed to evaluate the association between sex and tirofiban administration before EVT among patients enrolled in the RESCUE BT trial. Materials and methods This post hoc analysis used data from the RESCUE BT trial, which enrolled 948 patients with large vessel occlusion (LVO). Patients received intravenous tirofiban or a placebo before EVT. Comparisons between different groups were conducted using logistic regression. Additionally, the interaction between sex and treatment was tested. The primary effectiveness outcome was a modified Rankin Scale (mRS) score of 0–2 at 90 days; safety outcomes included symptomatic intracranial hemorrhage (sICH) within 48 h and mortality at 90 days. Results Of the 948 patients, 391 (41.2%) were women. The interaction between sex and treatment for a 90-day mRS score of 0–2 was not statistically significant ( P for interaction = 0.103). However, in the tirofiban arm, women were less likely to achieve an mRS score of 0–2 at 90 days (adjusted odds ratio (aOR), 0.57; 95% confidence interval (CI), 0.36–0.90; p = 0.02) compared to men. In analyses stratified by sex, tirofiban was not associated with improved functional outcomes compared to placebo in either women or men. No sex-related differences were observed in symptomatic intracranial hemorrhage within 48 h or mortality at 90 days. Conclusion In this exploratory analysis, no significant interaction between sex and treatment was identified, indicating that the association between tirofiban and 90-day outcomes did not differ by sex. Although women in the tirofiban arm had lower odds of achieving an mRS score of 0–2 at 90 days than men, this finding should be interpreted as hypothesis-generating and warrants further validation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied Large vessel occlusion stroke (n=948). Female sex (in tirofiban arm) vs. Male sex was evaluated on Modified Rankin Scale (mRS) score of 0-2 at 90 days (aOR 0.57, 95% CI 0.36-0.90, p=0.02). Among patients with large vessel occlusion stroke receiving tirofiban before endovascular treatment, women had lower odds of achieving functional independence at 90 days compared to men.
Synapse has enriched 10 related papers. Consider them for comparative context: